Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther Ads (NQ: ADAP )

5.050 USD -0.080 (-1.56%)
Official Closing Price Updated: 7:59 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Adaptimmune Ther Ads

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
BRIEF-Biolife Solutions executes supply agreement with Adaptimmune for Cryostor
* Biolife solutions executes supply agreement with adaptimmune for cryostor® use in spear t-cell platform 
Tags companyNews
From Reuters: Company News
Adaptimmune Therapeutics Becomes Oversold (ADAP)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
BRIEF-Adaptimmune announces data from NY-ESO study in Synovial Sarcoma at ASCO annual meeting
* Adaptimmune announces an oral presentation on data from NY-ESO study in Synovial Sarcoma and four trials in progress posters at the American Society Of Clinical Oncology (ASCO) annual meeting 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune Therapeutics says initiated study of NY-ESO SPEAR T?cells
* Adaptimmune Therapeutics Plc - initiated study of NY-ESO SPEAR T-cells targeting NY-ESO in combination with keytruda in patients with multiple myeloma 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune reports initiation of study to evaluate spear t-cell therapy
* Adaptimmune announces initiation of study to evaluate spear t-cell therapy targeting mage-a4 in multiple solid tumors 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune announces initiation of study to evaluate SPEAR T-cell therapy
* Adaptimmune announces initiation of study to evaluate SPEAR T-cell therapy targeting AFP in liver cancer Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune Q1 loss per share $0.05
* Adaptimmune therapeutics plc - offerings in march and april raised net proceeds of $103.2 million; operations funded through to late 2019 
Tags companyNews
From Reuters: Company News
Tocagen IPO Could Garner Significant Investor Attention
Tocagen Inc. is set to price its IPO today, the company plans to offer 7.25 million shares at an expected price range of $10-12. Tocagen's lead products are in Phase 2/3 of development. 
Tags Stocks / Equities Healthcare
From Blogs - TalkMarkets
BRIEF-Adaptimmune Therapeutics announces registered direct offering of ADS
* Adaptimmune therapeutics plc announces registered direct offering of american depositary shares 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune Therapeutics prices public offering of American Depositary Shares
* Adaptimmune Therapeutics PLC prices public offering of American Depositary Shares 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune Therapeutics proposes public offering of American Depositary Shares
* Adaptimmune Therapeutics Plc proposes public offering of American Depositary Shares 
Tags companyNews
From Reuters: Company News
Benzinga's Top Upgrades, Downgrades For March 17, 2017
Top Upgrades Wunderlich upgraded Adobe Systems Incorporated (NASDAQ: ADBE) from Hold to Buy. Adobe shares rose 5.23 percent ... 
Tags SNAP EXA Financials
From Benzinga
BRIEF-Adaptimmune Therapeutics names Helen Tayton-Martin as chief business officer
* Adaptimmune Therapeutics- appointment of co-founder, Helen Tayton-Martin to role of chief business officer, William (Bill) Bertrand, Jr., J.D., as COO Source text for Eikon: Further company... 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune Therapeutics reports Q4 loss per share $0.04
* Adaptimmune reports fourth quarter and full year 2016 financial results 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune Therapeutics reports Q4 revenue $8.5 mln vs $4 mln
* Adaptimmune reports fourth quarter and full year 2016 financial results 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune says confirms GSK nomination of second adaptimmune target under strategic multi-target collaboration
* Adaptimmune confirms gsk nomination of second adaptimmune target under strategic multi-target collaboration 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune, Bellicum Pharma collaborate to evaluate next-generation T-cell therapies
* Adaptimmune and Bellicum Pharmaceuticals enter a strategic collaboration to evaluate next-generation T-cell therapies 
Tags companyNews
From Reuters: Company News
Is Cascadian Therapeutics Inc (CASC) A Good Stock To Buy?
In this article, we take a closer look at Cascadian Therapeutics Inc. from the perspective of successful hedge funds. Is Cascadian Therapeutics Inc. a superb investment today? Hedge funds are... 
Tags Pharma/Biotech Financial Stocks / Equities
From Blogs - TalkMarkets
BRIEF-Adaptimmune announces initiation of myxoid/round cell liposarcoma study
* Adaptimmune announces initiation of myxoid/round cell liposarcoma study 
Tags companyNews
From Reuters: Company News
Calithera Pharma In Focus Part 1 - Checkpoint Inhibition
Clinical stage company Calithera presents an early stage investment opportunity with the ability to enhance therapeutic value to the first wave of IO therapeutics checkpoint inhibitors from Merck's... 
Tags Healthcare Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
BRIEF-Adaptimmune announces update on clinical data from NY-ESO Spear T-cell synovial sarcoma study
* Adaptimmune announces update on clinical data from NY-ESO Spear T-cell synovial sarcoma study at the 2016 annual meeting of the Connective Tissue Oncology Society (CTOS) 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune presents preclinical data from SPEAR T-cell
* Adaptimmune presents preclinical data from a new, wholly-owned Spear T-cell and a second generation spear T-cell at the 31st annual meeting of the Society For Immunotherapy for Cancer (sitc) 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune posts Q3 earnings per share of $0.04
* Q3 revenue view $5.3 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com) 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune announces removal of partial clinical hold in MRCLS
* Adaptimmune announces removal of partial clinical hold in myxoid/round cell liposarcoma (MRCLS) 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune announces board changes
* Adaptimmune announces board changes Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
BRIEF-Adaptimmune announces collaboration with MSD to evaluate Keytruda (pembrolizumab)
* Adaptimmune announces collaboration with MSD to evaluate Keytruda (pembrolizumab) in combination with NY-ESO SPEARt-cell therapy in multiple myeloma 
Tags companyNews
From Reuters: Company News
12 Biggest Mid-Day Losers For Monday
Tidewater Inc. (NYSE: TDW) shares dropped 44.3 percent to $1.66 after it was announced the company received only ... 
Tags Regional Banks ANCX INO
From Benzinga
BRIEF-Adaptimmune Therapeutics Plc announces initiation of triple tumor study
* Adaptimmune Therapeutics Plc - adaptimmune announces initiation of triple tumor study to evaluate its spear t-cell therapy targeting MAGE-A10 Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
Relative Strength Alert For Adaptimmune Therapeutics
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
12 Biggest Mid-Day Losers For Wednesday
Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC) shares dropped 19.1 percent to $5.67 after the company issued a profit ... 
Tags BSPM AA RXII
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.